Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

Digital technologies for medicines: shaping a framework for success

Regulatory agencies can provide advice to support developers of digital technologies for medicines use, but what are the best strategies to maximize the chance of a successful regulatory interaction? Here, EMA and industry representatives comment on the experience so far.
  1. Francesca Cerreta

    1. European Medicines Agency, Amsterdam, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Armin Ritzhaupt

    1. European Medicines Agency, Amsterdam, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Thomas Metcalfe

    1. F.Hoffmann-La Roche, Basel, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Scott Askin

    1. Novartis Pharma, Basel, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. João Duarte

    1. Alexion Europe, Levallois-Perret, France.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Michael Berntgen

    1. European Medicines Agency, Amsterdam, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  7. Spiros Vamvakas

    1. European Medicines Agency, Amsterdam, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

The technological and regulatory landscape for digital technologies in medicines development and use is rapidly evolving, as they are increasingly becoming part of the conduct of clinical trials. Examples include continuous patient monitoring for clinically relevant parameters, electronic data capture of laboratory values, direct data entry by clinicians into clinical record forms and facilitated collection of patient-reported outcomes.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature Reviews Drug Discovery 19, 573-574 (2020)

doi: https://doi.org/10.1038/d41573-020-00080-6

Acknowledgements

The authors acknowledge the contributions to this article of the following experts: C. Vincenzi (EMA); S. Corriol-Rohou (AstraZeneca); F. Albissola (Sanofi); S. Almeida (Medicines for Europe); M. vonFritschen (Eucope); A. Schepers (GSK), F. Ruediger (Grunenthal) and T. Chesworth (AstraZeneca).

Disclaimer

The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the organizations they are affiliated with, the European Medicines Agency or one of its committees or working parties.

Competing Interests

T.M. is employed by F. Hoffmann-La Roche and owns shares. S.A. is employed by Novartis Pharma and owns shares. J.D. is employed by Alexion and owns shares.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links